{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"}],"units":"Participants"}],"description":"To evaluate the safety/tolerability of X-396 (ensartinib) and determine the maximum tolerated dose (MTD) of X-396 as a single agent.","groups":[{"description":"All patients treated in the escalating doses from 25 mg -250 mg","id":"OG000","title":"Phase I/II X:396 Ensartinib"}],"paramType":"NUMBER","populationDescription":"Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy that is not responsive to at least 1 prior standard regimen for advanced disease or for which there is no approved therapy or for patients that decline standard therapy.Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1. For Phase study, patients must have NSCLC with ALK genomic alterations.","reportingStatus":"POSTED","timeFrame":"28 Days","title":"Maximum Tolerated Dose","type":"PRIMARY","unitOfMeasure":"mg"}